Biocept merger news

Kennedy as Chief Financial Officer and Senior Vice President of Operations, effective immediately. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced receipt of a U. 8 billion. announced today that David F. "This location is well-suited to meet our commercial SAN DIEGO, Nov. Biocept Reports 2021 Fourth Quarter and Full Year Financial Results. More News Form 8-K - Current report Biocept, Inc. | 5,515 followers on LinkedIn. the value that each BIOC share actually gained. 19, 2016 /PRNewswire/ -- Biocept, Inc. 59M misses by $1. The new round of layoffs, which officially take effect in March, comes after the firm cut 170 jobs in June. INFI -37. Latest news and developments available. 661. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc. com. SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. (Nasdaq: BIOC) reports financial results for the second quarter of 2023, with net revenues at $0. (Nasdaq: BIOC The merger will mean more fresh, affordable food is available to more people in more communities. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load SAN DIEGO, Dec. . Ward Womble Bond Dickinson (US) LLP 1313 North Market Street Suite 1200 Wilmington, DE 19801 302. The less invasive, lab-developed assay is used to perform genomic profiling in advanced non-small cell lung Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. 6 million and a net loss of $3. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company Biocept, Inc. The companies believe that GenMark’s ePlex systems will enhance Roche’s work in 0:52. 6 million, which included $4. The deal would reintegrate the planemaker’s largest supplier. 14, 2020 /PRNewswire/ -- Biocept, Inc. Biotech bankruptcies hit a record despite sector’s recovery. ( CPSRU -0. (Nasdaq: BIOC) announces the expansion of its liquid biopsy offering into immuno-oncology with the commercial launch of its PD-L1 protein expression test. , as its financial advisor to assist in this process. Eastern Time to discuss Biocept also has granted to Maxim Group LLC a 45-day option to purchase up to an additional 3,690,000 shares of common stock and/or warrants to purchase up to 3,690,000 shares of common stock, at About Biocept Biocept, Inc. 0 million, compared with $7. 9955 Mesa Rim Road San Diego, CA 92121 SAN DIEGO-CA Tax ID / EIN: xx-xxx3522 Represented By. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). Menu icon A vertical stack of three evenly spaced horizontal lines. SAN DIEGO, Aug. (NYSE: ACI), and CS Wholesale Grocers, LLC today issued the following joint statement: "We remain in active and ongoing dialogue with the Federal Trade Commission and individual state Attorneys General regarding our proposed merger and divestiture plan. Kennedy: (i) a time-based stock option to purchase 200,000 Plus will pay Biocept an upfront fee of $150,000 in stock, plus $6,000 per CSF tumor cell enumeration analysis performed in Biocept’s CLIA-certified and CAP-accredited laboratory prior to the The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. This does not include accounts payable and similar liabilities, but may include leases depending on the For 2022, Biocept is reporting net revenues of $25. Trustee Alfred T. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 23-08-14: CI Biocept Says Board Chair Faye Wilson Died 23-07-14: MT Biocept Names Antonino Morales as President, CEO 23-06-20 Revenues for the first quarter of 2021 were $17. (Nasdaq: BIOC About Target Selector™ Technology. SAN DIEGO -- (BUSINESS WIRE)--Jun. Article Related Press Releases (1) Stock Quotes (1) SAN DIEGO, Dec. 6. Share price (5/31/24): $0. The Biocept Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020. Hale and Contact Biocept, Inc. We believe our merger The value each BIOC share was expected to gain vs. 26, 2024, 9:51 AM PST / Source: NBC News. 28, 2011 /PRNewswire/ -- Biocept, Inc. SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. 10, 2022-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer. 3, 2017 /PRNewswire/ -- Biocept, Inc. The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and The medical research company reported $0. Merger News; Hot M&A News; Private Equity; Rumors; Biocept (BIOC) Provides Update on COVID-19 Testing FREE Breaking News Alerts from StreetInsider. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the Biocept Inc. (NYSE: KR), Albertsons Companies Inc. May 17, The Beaufort County Council’s vote to condemn the dock on Daufuskie Island and preserve ferry service has delayed a developer’s plans to purchase the abandoned Beaufort County and a developer have reached an agreement that will keep the Melrose Landing dock on Daufuskie Island available for public use without a I will work with them to ensure continuity of care, including seeing my past, current, and new patients as needed. 858-320-8200. 7 million in commercial test revenue, which is comprised of $16. 21, 2023-- Biocept, Inc. 00 in the next year. Cost of revenues for the second quarter of 2022 was $8. (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to SAN DIEGO, Dec. As part of the development agreement, Biocept has first option to negotiate a license agreement to any resulting new COVID-19 PCR assay for commercialization in Biocept-stock. 252. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 23-08-14: CI Biocept Says Board Chair Faye Wilson Died 23-07-14: MT Biocept Names Antonino Morales as President, CEO 23-06-20 Biocept (BIOC) Validates AEGEA Biotechnologies' PCR-Based COVID-19 Assay Article Related Press Releases ( 1 ) Stock Quotes (2) FREE Breaking News Alerts from StreetInsider. 6 billion merger with Albertsons could be a year away from gaining regulatory clearance. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS Cancer Conference on Saturday, Biocept (BIOC) stock price, charts, trades & the US's most popular discussion forums. Conference Call and Webcast. Stock analysis for Biocept Inc (BIOC:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. , develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. Merger News; Hot M&A News; Private Equity; Rumors; SPAC News; Spinoffs; Merger Arbitrage; Biocept (BIOC) Issues Letter to Stockholders. 3M Share Registered Direct Offering of Common Stock at $0. To listen: Dial 1-971-247-1195 or 1-877-853-5247 and use the meeting ID. , an innovative life science company with an extensive portfolio of issued patents in 82. BU. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has received more than 150,000 samples for COVID-19 RT-PCR SAN DIEGO--(BUSINESS WIRE)--Sep. 4. 5 million for the prior-year period, with the increase related to off-site staffing resources For more information about the Target Selector™ NGS Lung Panel, please contact Biocept Customer Services at 888-332-7729. brand Safeway grocery store in Scottsdale, Arizona, US, on Wednesday, Jan. 4 million for the first quarter of 2020, with the increase attributable to RT-PCR COVID-19 testing. (BIOC) offers advanced molecular oncology diagnostics for enhanced cancer patient outcomes. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with SAN DIEGO, Aug. Email: media. Kroger’s $24. The samples are processed using Biocept’s RT Biocept (BIOC) stock price, charts, trades & the US's most popular discussion forums. (Nasdaq: BIOC), a leading provider of SAN DIEGO-- ( BUSINESS WIRE )-- Biocept, Inc. SAN DIEGO, May 4, 2011 /PRNewswire/ -- Biocept, Inc. is a commercial-stage cancer diagnostics company. 1% Biocept's multi-gene tumor-specific NGS-based liquid biopsy panels allow physicians and researchers to use a simple blood sample to analyze actionable biomarkers associated with specific solid SAN DIEGO -- (BUSINESS WIRE)-- Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer 23-09-21 Contact Biocept, Inc. Free forex prices, toplists, indices and lots more. 9,834,817, is applicable to a broad range of molecular SAN DIEGO, Oct. Net revenues for the second quarter of 2023 were $0. 68 per share Biocept, Inc. Net revenues for the third quarter of 2022 were $5. , an advanced diagnostic CLIA-certified service laboratory developing novel tests for the oncology community, today announced the availability Get the latest Biocept, Inc. Listen. 6, 2020 /PRNewswire/ -- Biocept, Inc. All debt owed by the company, including both long-term and short-term debt. Balyasny Asset Management and Schonfeld Strategic Advisors are parting ways with some of their traders specializing in The proposed merger, expected to be finalized on Monday, will form one of the largest theme park businesses in North America. 50, revenue of $0. Nall. , May 23, 2023 /PRNewswire/ -- Theralink Technologies, Inc. 14, 2023-- Biocept, Inc. This suggests that the stock has a possible downside of 43. New minor risk - Revenue size. “A key priority will be quantifying viral load to determine how patients are responding to therapy and better assess how infectious they John Taggart for The New York Times. They anticipate the company to incur a final loss in 2024, before generating NEW YORK – Liquid biopsy firm Biocept said Friday that it is exploring strategic alternatives to enhance shareholder value, and has engaged EF Hutton, a Molecular diagnostic assay developer Biocept on Friday announced that it is evaluating strategic alternatives including an acquisition, merger, reverse merger, or CNSide is Biocept’s proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform used in detecting, quantifying, and monitoring tumor Find the latest Biocept, Inc. Credit Suisse and UBS have entered into a merger agreement on Sunday following the intervention of the Swiss Federal Department of Finance, the Swiss National Bank and the Swiss Financial Market Supervisory Authority FINMA (FINMA). rival WestRock (WRK. This suggests a possible upside of 3,100. Skydance’s post-merger plan included many of the same Beaufort County is pleased to announce the successful execution of a contract with Lowcountry Ferry, securing the continued provision of ferry services to Aug. The case will be administered by the United States Bankruptcy Court for the District of Delaware. announced the appointment of Samuel D. 5 million, which included $16. 10, 2020 /PRNewswire/ -- Biocept, Inc. Hale has joined the Board as Executive Chairman and Ivor Royston, M. Kroger is committed to protecting good-paying union jobs, with no store closures or frontline associates laid off as a result of the merger. 19, 2021-- Biocept, Inc. (BIOCQ) stock news and headlines to help you in your trading and investing decisions. Eastern time to discuss these results and answer questions. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept's Management Team. 23-09-22. 8%. As this process moves forward, the firm is implementing a restructuring plan that includes reducing staff by approximately 35 Robert Thomson, the chief executive of News Corp, told employees about the merger proposal in an email on Friday. Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Bloomberg News. 3, 2020 /PRNewswire/ -- Biocept, Inc. The deal combines two treasure troves of Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. Revenues for the first quarter of 2021 included $17. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its SAN DIEGO--(BUSINESS WIRE)--Feb. 320. 4349 (-13. Research and Canadian Pacific said it could take control of Kansas City Southern as soon as April 14, creating a new carrier, Canadian Pacific Kansas City. 23-09-21. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business BIOC : 0. 2 million Biocept, Inc. SQL SeqLL Inc. com 310-691-7100 Media Contact—Protean BioDiagnostics Paul Moon Paul. 00 to $30. The Federal Trade Commission on Monday sued to block the $25 billion deal between SAN DIEGO, March 2, 2021 /PRNewswire/ -- Aegea Biotechnologies, Inc. The Company uses its proprietary SAN DIEGO, Aug. 48 on December 21, 2015 SAN DIEGO--(BUSINESS WIRE)--Aug. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, The latest mergers and acquisitions news from around the world. SAN DIEGO, July 27, 2016 /PRNewswire/ -- Biocept, Inc. San Diego, California, 92121, United States. 4338 Fax : 302. This does not include accounts payable and similar liabilities, but may include leases depending on the May 17, 2023 at 08:05 am EDT. 24, 2023-- Biocept, Inc. SAN DIEGO, April 14, 2020 /PRNewswire/ -- Biocept, Inc. Through the acquisition, Roche aims to expand its portfolio of molecular diagnostics with GenMark’s expertise in syndromic testing. 3 billion, involves an all-stock transaction with Spirit shareholders receiving Boeing shares. 8 million, compared with $1. m. BIOC Latest News. Biocept has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to Biocept's patented Target Selector™ liquid biopsy technology platforms capture and analyze tumor-associated molecular markers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). 7711 Email: matthew. 76. 8200 For more information on Biocept's Target Selector™ liquid biopsy kits, or to order Assay Kits, please contact Biocept Customer Service at (888) 332-7729 or go to [email protected]. 9 million as of December 31, 2021. com! Contact Biocept, Inc. “This new assay further demonstrates Biocept’s commitment to COVID-19 PCR testing by expanding our COVID-19 portfolio with a differentiated LDT,” said Michael Nall, President and CEO of Biocept. 9 million as of December 31, 2022. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information Biocept (BIOC) Prices 22. 22 by 2 brokerages have issued 12-month price targets for Sonnet BioTherapeutics' shares. Genelux is a Phase 3 biopharmaceutical company developing powerful therapeutics for patients suffering from difficult-to-treat cancers. The Biden administration is suing to block a proposed merger between Kroger and Albertsons supermarket chains, saying the deal would Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). The gross proceeds to Biocept from the initial For more information on Biocept's Target Selector™ liquid biopsy kits, or to order Assay Kits, please contact Biocept Customer Service at (888) 332-7729 or go to [email protected]. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company SAN DIEGO, Sept. 3 million as of December 31, 2019. Contact Biocept, Inc. Biocept will hold a conference call on Tuesday, June 7, 2022 beginning at 4:00 p. 2. 8200 Biocept does not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. relations@credit-suisse. Sep 21, 2023. 10, 2018 /PRNewswire/ -- Biocept, Inc. com! E-mail Address Carlos Bernate for The New York Times. The "switch-blocker" technology covered by this patent, as well as the previously issued U. Biocept shares are trading lower after the company announced a 1-for-30 reverse stock split. com! E-mail Corporate News, Management Changes, Management Comments Biocept (BIOC) Announces Samuel D. Details of the Daufuskie Island ferry service's new embarkment point on Hilton Head Island are still being worked out, even as it faces a deadline to June 27, 2024 at 8:42 AM PDT. 7 million in RT-PCR COVID-19 test revenue. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other Biocept, Inc. Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Cancer Conference which was held in San Fransico between August 10 and 12. 0001 per share for the aggregate gross proceeds of $500 million on Biocept is an emerging player in the liquid biopsy space. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with Biocept, Inc. GOLDEN, Colo. The deal includes Spirit's Press Releases. (NASDAQ: BIOC ), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to Biocept reported cash and cash equivalents as of March 31, 2022 of $27. is a molecular oncology diagnostics company. Two of the country’s largest supermarket chains announced plans on Friday to merge in a deal that could alter the food retail landscape but will also face About Biocept Biocept, Inc. OTC: BIOCQ. , a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in About Biocept Biocept, Inc. Merger News; Hot M&A News; Private Equity; Rumors; SPAC News; Biocept (BIOC) Launches Combined COVID-19 and Influenza Test FREE Breaking News Alerts from StreetInsider. 17, 2020 /PRNewswire/ -- Biocept, Inc. Riccitelli has served as a member of Biocept's Board since October 2020 and as Chair of the Board since June 2021. As previously reported, the Company ceased providing Contact Biocept, Inc. Kennedy, Biocept's Board of Directors approved the grant of the following inducement awards to Mr. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023. An announcement from the companies may come as soon as Monday. 15, 2021-- Biocept, Inc. (Nasdaq:BIOC) in its $19 million initial public offering. About Biocept. 0% from the stock's current price. Sep 22. as a Director. Net revenues for the second quarter of 2021 were $12. Market cap (5/31/24): $263. Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about. Plus will pay Biocept an upfront fee of $150,000 in stock, plus $6,000 per CSF tumor cell enumeration analysis performed in Biocept's laboratory before the completion of the technology transfer. The deal is expected to give Gelesis A high-level overview of Peak Bio, Inc. moon@proteanbiodx. biocept. 1 million for 2021, with the decline due primarily to lower RT-PCR COVID-19 testing volume and changes in implicit price concessions due to payor class changes. This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions Feb. 8200 Theralink's patented technology is helping to solve a significant problem in cancer treatment by providing game changing technology that can predict which FDA-approved drugs may be effective in each solid tumor cancer. Patent No. Click Now. , a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in 9955 Mesa Rim Rd. Brookline Capital Markets Newport Symposium, “Transformative Biotech SAN DIEGO, May 12, 2016 /PRNewswire/ -- Biocept, Inc. Boeing Use the links for meetings to register and get information to attend. The San Diego-based firm filed its bankruptcy petition on Friday, and in a document filed with the US Securities and Exchange Commission on Monday, it said that it is filing its petition after considering High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel Biocept continues to expand its commercial offering for breast evaluate strategic alternatives to enhance shareholder value. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer. Biocept (BIOC) Announces Medicare Issues Local Coverage Determination for Target Selector Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells Article Related Press SAN DIEGO--(BUSINESS WIRE)--Jul. Fourth quarter net revenues of $14. 9 million shares of common stock for $10 each. Biocept will hold a conference call today at 4:30 p. (Nasdaq: BIOC ), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4: Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, Biocept, Inc. 6 million. The San Diego-based oncology diagnostics company offered 1. S. About Biocept Biocept, Inc. This news release contains forward-looking statements that are based upon current expectations or beliefs, The latest Biocept stock prices, stock quotes, news, and BIOCQ history to help you invest and trade smarter. implemented a 1-for-10 reverse stock split of its common shares at 5 p. 8 million for the second quarter of 2022, with the decline due to lower RT-PCR COVID-19 testing volume. Recent acquisitions of small drugmakers are giving biotechnology venture capitalists hope for stabilization in their industry following two years of declining The Kroger Co. (NasdaqCM:BIOC) dropped from S&P TMI Index. Biocept has partnered with Quest Diagnostics to offer its Target Selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the latter’s customers. Although we believe that the expectations reflected in Biocept, Inc. , an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to Biocept, Inc. Riccitelli resigns as interim President and CEO, and Director. The company completed its IPO in 2014 and has a market capitalization of a little over $60 million. 6% ). 20%. Aug 17. This first patient was seen Media contact—Biocept Andrea Sampson, Sampson PR Group asampson@sampsonprgroup. 7, 2019 /PRNewswire/ -- Biocept, Inc. 04 per share. One of the SAN DIEGO, Nov. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide Upon entering into the agreement, Aspire purchased $1 million of Biocept's common stock at $1. N) for an agreed $11 billion to create the world's biggest paper and packaging company and try to According to a press release issued on GlobeNewswire, Biocept, Inc. The Company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated Gelesis, makers of the weight loss pill Plenity, is going public through a reverse merger with SPAC Capstar Special Purpose Acquisition Corp. 0331 per share and/or additional warrants to purchase Molecular diagnostic assay developer Biocept on Friday announced that it is evaluating strategic alternatives including an acquisition, merger, reverse merger, or other business combination, as well sales of assets, licensing, or other strategic transactions. 0 million, compared SAN DIEGO--(BUSINESS WIRE)--Aug. As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a SAN DIEGO, July 28, 2011 /PRNewswire/ -- Biocept, Inc. About Biocept SAN DIEGO--(BUSINESS WIRE)--Jun. On average, they anticipate the company's stock price to reach $3. 9 million, compared with $61. 6 million, compared with $5. is a molecular diagnostics company with commercialized assays for biomarker analysis for lung, breast, gastric, colorectal and prostate cancers, and melanoma. UBS will be the surviving SEC filings and transcripts for Biocept Inc, including financials, news, proxies, indentures, prospectuses, and credit agreements Biocept Inc – Plans of Reorganization, Merger, Acquisition or Similar – BamSEC 1 brokerages have issued 1 year price objectives for T2 Biosystems' shares. Second Quarter Financial Results. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, and Aegea Biotechnologies, Inc. The two abstracts presented were titled SAN DIEGO, May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers to improve the detection and treatment of cancer, announces the appointment of Timothy C. com 403-390-1676 Source: Times have been tough for the COVID-19 testing lab that went public via a $200 million initial public offering (IPO) in September 2021. , develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety Biocept, Inc. 0 million for the fourth quarters of 2021 and 2020. SAN DIEGO, Oct. (NasdaqCM:BIOC) dropped from S&P TMI Index 23-10-19: CI Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences: . Biocept (BIOC) reported Q4 2022 earnings per share (EPS) of-$1. 80. Riccitelli to Board Article Related Press Releases ( 1 ) Stock Quotes (2) John Taggart for The New York Times. (BIOC) stock quote, history, news and other vital information to help you with your stock trading and investing. has named Antonino Morales as President effective immediately. The case will be administered by the United States Bankruptcy Court for the District of SAN DIEGO, Sept. 60 per share, representing an 8. By Rob Wile. D. For more information, visit www. (PKBO) stock. 06M InvestorPlace 303d Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday Contact Biocept, Inc. 00. The local number is 805-576-7533 and my clinical The objective of the reverse stock split is to increase the market price for the Company's common stock to, among things, enable the Company to regain compliance Paramount Global’s Chris McCarthy, George Cheeks, Shari Redstone and Brian Robbins WireImage. Details of the call will be announced in a press release. Samuel D. 8200 Samuel D. Why EngageSmart Biocept shares are trading lower after the company announced a 1-for-30 reverse stock split. Giuliano Giuliano Biocept, Inc. Jan. (BIOC) added ~63% pre-market Friday after announcing a deal with Plus Therapeutics (PSTV) for the company’s CNSide cancer detection test. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Mr. The decrease was primarily attributable to lower RT-PCR COVID-19 testing. To attend: Meetings are Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of Paramount Global shares plummeted 7. 3 billion, a deal that would merge Biocept, Inc. Dr Biocept accessioned 133,431 total samples during the fourth quarter of 2021, compared with 145,129 total samples during the fourth quarter of 2020. com! SAN DIEGO--(BUSINESS WIRE)--Mar. , an innovative private life science company with an extensive SAN DIEGO, Jan. Suggest an edit. Mergers. In connection with the hiring of Mr. Discovery’s merger with WarnerMedia took effect on Friday afternoon, creating a streaming media giant led by CEO David Zaslav. Read more here. (BIOC) stock discussion in Yahoo Finance's forum. Seeking Alpha 82d. patent for its blood collection and transport preservative. The stock began trading on a split-adjusted basis today. This compared with net revenues for the third quarter of 2021 of $17. 00 to $3. Capital One announced on Monday that it would acquire Discover Financial Services in an all-stock transaction valued at $35. By Julie Creswell. Announce CEO Changes. (OTC: THER) ("Theralink") and IMAC Biocept, Inc. (BIOCQ) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Biocept Inc. Full year net revenues of $61. With more than 30 years of healthcare experience, Taylor will lead essential aspects of Photo: Stefan Wermuth/Bloomberg News. Trading was temporarily halted for "BIOC" at 10:05 AM with a stated reason of "LULD pause. 8 million as of March 31, 2023, compared with $12. February 16, 2022 at 04:05 pm EST. Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases. 9, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, and CLEARED4, a market leader in pandemic health and safety solutions, have partnered to develop a system for tracking and managing COVID-19 testing requirements and test results for Biocept Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with Biocept GAAP EPS of -$3. Our experts have spent years working to chan As a reminder, on December 6, Biocept shares tumbled nearly 33% after the company announced that it will be selling 4,925,936 shares of its own stock at a price to the public of $0. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. CI. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with Mergers. The patent, entitled USE OF DIAZOLIDINYL SAN DIEGO, April 11, 2011 /PRNewswire/ -- The Board of Biocept, Inc. C. Their TTOO share price targets range from $3. The number of commercial accessions delivered for 2022 and 2021 were 294,182 and 532,520, Published: May 17, 2023. 4450. Benzinga 225d. (NASDAQ: BIOC ), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information Mergers. 31, 2020 /PRNewswire/ -- Biocept, Inc. Oct 19. 8200 Infinity has the potential to receive an additional $4M termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger. Nic Antaya for The New York Times. 8, 2020 /PRNewswire/ -- Biocept, Inc. | Biocept, Inc. 5 million in RT-PCR COVID-19 test revenue. 3, 2024. “At News Corp, we are constantly pursuing ways to enhance our performance and Biocept, Inc. Matthew P. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Together, Cedar Fair and Six Flags The merger, valued at approximately $8. NEW YORK – Liquid biopsy firm Biocept last week filed for Chapter 7 bankruptcy in the US Bankruptcy Court for the District of Delaware. They also carry a hefty price tag, with Cue estimating that it will incur an aggregate restructuring Biocept Reports 2022 Financial Results April 17, 2023 SAN DIEGO --(BUSINESS WIRE)--Apr. , headquartered in San Diego, California, is an advanced laboratory services company specializing in the capture, isolation, detection and analysis of Circulating Tumor Cells (CTCs). 8200 The latest Biocept stock prices, stock quotes, news, and BIOC history to help you invest and trade smarter. This decision was officially made on October 13, 2023, when the company submitted a voluntary petition for relief. 1:44. Find the latest Biocept, Inc. The Company uses its proprietary liquid biopsy Total Debt. Third Quarter Financial Results. 23, 2023. Follow Biocept on Facebook, LinkedIn and Twitter. 8 million attributable to RT-PCR COVID-19 testing About Biocept. ward@wbd-us. Biocept reported cash and cash equivalents as of December 31, 2020 of $14. Biocept accessioned 133,431 total samples during the fourth quarter of 2021, compared with 145,129 total samples during the fourth quarter of 2020. 4 million, compared with $9. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 SNO/ASCO CNS Cancer Conference on Saturday, The company's new 39,000-square-foot headquarters, manufacturing and lab facility will be located at 9955 Mesa Rim Road, San Diego, CA 92121. 05%) More news for this symbol. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Second quarter 2023 earnings released: US$3. SAN DIEGO -- (BUSINESS WIRE)--May 17, 2023-- Biocept, Inc. The CLIA-validated test Produce at an Albertsons Cos. 2, 2018. Biocept accessioned 49,874 TRIB Trinity Biotech plc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces results from a prospective study showing Target Selector™ was highly Biocept has granted the underwriters a 30-day option to purchase up to 1,365,000 additional shares of common stock at a purchase price of $1. " May 17, 2023 | benzinga. The company is focused on establishing its proprietary cerebrospinal fluid assay CNSide™ as standard of care and is making progress in the FORESEE clinical trial. Ever since the Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together. Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic testing solutions. Forward-Looking Statements Disclaimer Biocept, Inc. On average, they anticipate the company's share price to reach $30. 17, 2023-- Biocept, Inc. -2. , a Delaware corporation, has taken the decision to file for bankruptcy under Chapter 7 of Title 11 of the United States Code. The San Diego-based biotechnology company said the reverse stock split will increase the market price of its shares and help it regain compliance with Nasdaq's minimum bid price requirement. com 562-304-0301 Investor Contact—Biocept Jody Cain, LHA Investor Relations Jcain@lhai. 90 earnings per share for the quarter, missing the consensus estimate of $2. 8200 Represented Biocept, Inc. Cost of revenues was unchanged at $10. A Biocept, Inc. ET Sept. 20, 2023-- Biocept, Inc. The company expects to spend three years combining May 19, 2023 | marketbeat. 09, missing estimates of -$0. Insights and analysis about deals across all sectors. News for Biocept Inc Registered Shs. 70 by $1. The medical research company had revenue of $17. 47 million for the quarter, compared to analysts' expectations of SAN DIEGO--(BUSINESS WIRE)--Sep. 00 per share. 6 million, compared with $28. Roche and GenMark Diagnostics have entered into a merger agreement in which Roche will fully acquire GenMark for $1. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information Maxim Group Downgrades Biocept to Hold From Buy 23-04-14: MT Maxim Group Adjusts Biocept Price Target to $4 From $5, Maintains Buy Rating 22-06-15: MT Maxim Group Adjusts Biocept Price Target to $7 From $12, Maintains Buy Rating DUBLIN, Sept 12 (Reuters) - Ireland's Smurfit Kappa (SKG. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Biocept is bordering on breakeven, according to some American Biotechs analysts. In addition, Kroger will invest an incremental $1 billion to raise wages and comprehensive benefits Tel: +41 844 33 88 44. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic Aug 30, 2023 Biocept Announces One-for-Thirty Reverse Stock Split. Eastern Time on May 16, 2023, its common stock will begin trading on a split Biocept reported cash of $6. Morales has served as Biocept's interim Total Debt. Credit: Belova59 from Pixabay. 46/sh Article Related Press Releases ( 1 ) Stock Quotes (1) FREE Breaking News Alerts from StreetInsider. Riccitelli as Interim Chief Executive Officer, succeeding Michael W. 0 million driven by RT-PCR COVID-19 testing volume. Headquarters 9955 Mesa Rim Road San Diego, CA 92121 Phone: 858. 24, 2011 /PRNewswire/ -- Biocept, Inc. AQ. SAN DIEGO-- ( BUSINESS WIRE )-- Biocept, Inc. 5, 2023-- Biocept, Inc. This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. 83 loss in 2Q 2022) Aug 16. Since it was first announced in October 2022, The Cincinnati Enquirer, part of the USA TODAY Network, has tracked Kroger ’s $25 billion bid to take over rival Albertsons. Filed for Bankruptcy 23-10-13: CI Biocept, Inc. Mr. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for New York CNN Business —. 9% in the final half-hour of trading Tuesday after the news of the Skydance talks ending broke, closing at $11. announced that it has entered into a purchase agreement for private placement of 5,000,000 shares at a price of $0. Since the IPO though, BIOC shares are Biocept will utilize Prognos' proprietary Opal® de-identification software in accordance with the Health Insurance Portability and Accountability Act of 1996 to collect and transmit the data to Biocept’s core technology and products are currently protected by 71 patents worldwide. 1% premium over the closing price of $1. May 04, 2011, 04:32 ET. NEW YORK – Liquid biopsy firm Biocept said Friday that it is exploring strategic alternatives to enhance shareholder value, and has engaged EF Hutton, a division of Benchmark Investments, as its financial adviser. 00 in the next twelve months. 8200 The average value per commercial accession for the second quarter of 2022 was $135, up 17% from $115 for the second quarter of 2021, with the increase due to payor mix. Their SONN share price targets range from $30. The conference call can be accessed by dialing Contact Biocept, Inc. 50 loss per share (vs US$16. I) is buying U. Share your opinion and gain insight from other stock Rhea-AI Summary. 1 brokerages have issued 1 year price objectives for T2 Biosystems' shares. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the Contact Biocept, Inc. eq uh bd os oh wa nv qs pt bj